Viewing Study NCT02292732


Ignite Creation Date: 2025-12-24 @ 9:43 PM
Ignite Modification Date: 2026-03-29 @ 11:17 PM
Study NCT ID: NCT02292732
Status: WITHDRAWN
Last Update Posted: 2016-01-26
First Post: 2014-11-13
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors
Sponsor: GlaxoSmithKline
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Pharmacokinetics View
None Solid Tumors View
None Safety View
None Trametinib View
None MEK Inhibitor View
None Combined Oral Contraceptive View
None Trametinib's Metabolite M5 View
None Norethindrone View
None Ethinyl Estradiol View